TR201905217T4 - Kopanlisib ve bunun dihidroklorid tuzunun sentezi. - Google Patents

Kopanlisib ve bunun dihidroklorid tuzunun sentezi. Download PDF

Info

Publication number
TR201905217T4
TR201905217T4 TR2019/05217T TR201905217T TR201905217T4 TR 201905217 T4 TR201905217 T4 TR 201905217T4 TR 2019/05217 T TR2019/05217 T TR 2019/05217T TR 201905217 T TR201905217 T TR 201905217T TR 201905217 T4 TR201905217 T4 TR 201905217T4
Authority
TR
Turkey
Prior art keywords
kopanlisib
dihydrochloride
synthesis
dihydrochloride salt
copanlisib
Prior art date
Application number
TR2019/05217T
Other languages
English (en)
Inventor
Peters Jan-Georg
Rubenbauer Philipp
Gotz Daniel
Grossbach Danja
Mais Franz-Josef
Schirmer Heiko
Stiehl Juergen
Lovis Kai
Lender Andreas
Seyfried Martin
Zweifel Theodor
Marty Maurus
Weingärtner Gunter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of TR201905217T4 publication Critical patent/TR201905217T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Mevcut buluş, kopanlisib, kopanlisib dihidroklorid veya kopanlisib dihidroklorid hidratlarının hazırlanmasına yönelik yeni bir yöntem ile, yeni ara bileşikler ile ve söz konusu kopanlisib, kopanlisib dihidroklorid veya kopanlisib dihidroklorid hidratlarının hazırlanmasına yönelik söz konusu yeni ara bileşiklerin kullanımı ile ilgilidir. Mevcut buluş ayrıca bileşikler olarak kopanlisib dihidroklorid hidratları ile ilgilidir.
TR2019/05217T 2014-11-07 2015-11-05 Kopanlisib ve bunun dihidroklorid tuzunun sentezi. TR201905217T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14192203.9A EP3018127A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt

Publications (1)

Publication Number Publication Date
TR201905217T4 true TR201905217T4 (tr) 2019-05-21

Family

ID=51866061

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05217T TR201905217T4 (tr) 2014-11-07 2015-11-05 Kopanlisib ve bunun dihidroklorid tuzunun sentezi.

Country Status (47)

Country Link
US (1) US10494372B2 (tr)
EP (2) EP3018127A1 (tr)
JP (1) JP6691115B2 (tr)
KR (1) KR102566834B1 (tr)
CN (1) CN107278204B (tr)
AR (1) AR102570A1 (tr)
AU (1) AU2015341788B2 (tr)
BR (1) BR112017009470B1 (tr)
CA (1) CA2966800C (tr)
CL (1) CL2017001131A1 (tr)
CO (1) CO2017004532A2 (tr)
CR (1) CR20170184A (tr)
CU (1) CU24489B1 (tr)
CY (1) CY1121602T1 (tr)
DK (1) DK3215493T3 (tr)
DO (1) DOP2017000112A (tr)
EA (1) EA035558B1 (tr)
EC (1) ECSP17027755A (tr)
ES (1) ES2721778T3 (tr)
HK (1) HK1245774A1 (tr)
HR (1) HRP20190720T1 (tr)
HU (1) HUE042866T2 (tr)
IL (1) IL251874A0 (tr)
JO (1) JO3644B1 (tr)
LT (1) LT3215493T (tr)
MA (1) MA40895B1 (tr)
ME (1) ME03358B (tr)
MX (1) MX366904B (tr)
MY (1) MY189852A (tr)
NI (1) NI201700054A (tr)
NZ (1) NZ731287A (tr)
PE (1) PE20170897A1 (tr)
PH (1) PH12017500833A1 (tr)
PL (1) PL3215493T3 (tr)
PT (1) PT3215493T (tr)
RS (1) RS58579B1 (tr)
SA (1) SA517381462B1 (tr)
SG (1) SG11201703702RA (tr)
SI (1) SI3215493T1 (tr)
SV (1) SV2017005433A (tr)
TN (1) TN2017000179A1 (tr)
TR (1) TR201905217T4 (tr)
TW (1) TWI697495B (tr)
UA (1) UA122398C2 (tr)
UY (1) UY36392A (tr)
WO (1) WO2016071435A2 (tr)
ZA (1) ZA201703867B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JP6368353B2 (ja) 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
AU2016231259A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
TWI794288B (zh) 2017-09-08 2023-03-01 德商拜耳製藥公司 科帕利普(copanlisib)調配物
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2023139125A1 (en) 2022-01-18 2023-07-27 Synthon B.V. Improved process for preparation of copanlisib
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003580A (en) 1910-08-10 1911-09-19 Remington Typewriter Co Type-writing machine.
US6221877B1 (en) * 2000-04-12 2001-04-24 Regents Of The University Of California Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
EP1417204B1 (en) * 2001-08-15 2006-01-18 E. I. du Pont de Nemours and Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
PL226562B1 (pl) 2002-09-30 2017-08-31 Bayer Pharmaceuticals Corp Skondensowane pochodne azolopirymidyn, leki zawierające takie pochodne oraz ich zastosowanie
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2244721A4 (en) 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
JP6368353B2 (ja) 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
KR20180013850A (ko) 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
AU2016231259A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US20190382839A1 (en) 2016-02-01 2019-12-19 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
SG10202007262PA (en) 2016-02-01 2020-09-29 Bayer Pharma AG Copanlisib biomarkers
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors

Also Published As

Publication number Publication date
ME03358B (me) 2019-10-20
CO2017004532A2 (es) 2017-07-19
JP2017534631A (ja) 2017-11-24
SI3215493T1 (sl) 2019-05-31
CY1121602T1 (el) 2020-05-29
CU20170061A7 (es) 2017-10-05
HRP20190720T1 (hr) 2019-06-14
JP6691115B2 (ja) 2020-04-28
CU24489B1 (es) 2020-12-17
UY36392A (es) 2016-06-30
TN2017000179A1 (en) 2018-10-19
KR20170082563A (ko) 2017-07-14
TWI697495B (zh) 2020-07-01
JO3644B1 (ar) 2020-08-27
RS58579B1 (sr) 2019-05-31
NI201700054A (es) 2017-07-17
WO2016071435A3 (en) 2016-06-30
EP3018127A1 (en) 2016-05-11
AU2015341788A1 (en) 2017-05-18
CR20170184A (es) 2017-06-20
US20180282337A1 (en) 2018-10-04
EP3215493A2 (en) 2017-09-13
ES2721778T3 (es) 2019-08-05
ZA201703867B (en) 2019-07-31
EA035558B1 (ru) 2020-07-07
HK1245774A1 (zh) 2018-08-31
DK3215493T3 (da) 2019-05-06
UA122398C2 (uk) 2020-11-10
MA40895B1 (fr) 2019-07-31
PT3215493T (pt) 2019-05-21
AU2015341788B2 (en) 2020-01-16
EP3215493B1 (en) 2019-01-23
BR112017009470A2 (pt) 2018-01-02
DOP2017000112A (es) 2017-06-15
MX2017005893A (es) 2017-06-30
BR112017009470B1 (pt) 2022-11-01
EA201790983A1 (ru) 2017-10-31
SA517381462B1 (ar) 2021-01-25
AR102570A1 (es) 2017-03-08
CL2017001131A1 (es) 2018-01-19
CN107278204B (zh) 2019-12-17
MA40895A (fr) 2017-09-13
MX366904B (es) 2019-07-30
NZ731287A (en) 2023-01-27
ECSP17027755A (es) 2017-06-30
CN107278204A (zh) 2017-10-20
US10494372B2 (en) 2019-12-03
TW201625634A (zh) 2016-07-16
WO2016071435A2 (en) 2016-05-12
IL251874A0 (en) 2017-06-29
HUE042866T2 (hu) 2019-07-29
PH12017500833A1 (en) 2017-10-18
CA2966800C (en) 2023-02-21
MY189852A (en) 2022-03-14
PL3215493T3 (pl) 2019-07-31
SV2017005433A (es) 2018-04-30
LT3215493T (lt) 2019-04-25
PE20170897A1 (es) 2017-07-12
KR102566834B1 (ko) 2023-08-16
SG11201703702RA (en) 2017-06-29
CA2966800A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
TR201905217T4 (tr) Kopanlisib ve bunun dihidroklorid tuzunun sentezi.
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
PH12016502177A1 (en) Processes of preparing a jak1 inhibitor and new forms thereto
TR201904346T4 (tr) Copanlisib ve bunun dihidroklorür tuzunun sentezi.
EA201692219A1 (ru) Способы получения противовирусных соединений
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112016027455A2 (pt) moduladores ppar
EA201791645A1 (ru) Новые соли и полиморфы scy-078
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
IN2014MU00070A (tr)
IN2013MU01524A (tr)
TR201910829T4 (tr) Piripiropen bileşiği hazırlama metodu.
IN2014MU00069A (tr)
IN2013CH05394A (tr)